维普期刊资源整合服务平台（V6.5）

63篇 您的检索式：作者名="Bedikian"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Colorectal Cancer in Young Adults显示文摘	AGOP Y. BEDIKIAN HAGOB KANTARJIAN ROBERT S. NELSON JOHN R. STROEHLEIN GERALD P. BODEY	1981	Southern Medical Journal1981，，8：	1
2	A phase Ⅱ trial of arsenic trioxide in patients with metastatic melanoma显示文摘	Kim K B Bedikian A Y Camacho L H	2005	Cancer2005，104，8：	1
3	Bcl-2 antisense(oblimersen sodium)plus dacarbazine in patients with advanced melanoma:the Oblimersen Melanoma Study Group显示文摘	Bedikian A Y Millward M Pehamberger H	2006	J Clin Oncol2006，24，29：	1
4	Bcl-2 antisense(oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group显示文摘	Bedikian AY Millward M Pehamberger H	2006	J Clin Oncol2006，24，29：	1
5	Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma:the Oblimersen Melanoma Study Group显示文摘	Bedikian AY Millward M Pehamberger H		0，，29：	1
6	Sequential bioehemotherapy versus chemotherapy for metastatic melanoma;results from a phase III randomized trial显示文摘	Eton O Legha SS Bedikian AY	2002	J Clin Oncol2002，20，8：	1
7	Allovectin-7 therapy in metastat ic melanoma显示文摘	Bedikian A Y Del Vecchio M	2008	Expert Opin Biol Ther2008，8，6：	1
8	Predictive factors forthe development of brain metastasis in advanced unresectablemetastatic melanoma显示文摘	Bedikian AY Wei C Detry M	2011	Am J Clin Oncol2011，34，6：	1
9	LDH is a prognostic factor in stage IV patients but is a predictive factor only for bcl2 antisense efficacy: Re-analysis of GM301 and EORTC18951 randomized trials 显示文摘	Keilholz U Suciu S Bedikian CJ	2007	J Clin Oncol2007，25，：	1
10	Metastatic uveal melanoma therapy : current op-tions显示文摘	Bedikian AY	2006	Int Ophthalmol Clin2006，46，1：	1
11	Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group 显示文摘	Bedikian AY Millward M Pehamberger H	2006	J Clin Oncol2006，24，29：	1
12	Metastatic uveal melanoma therapy: current options显示文摘	Bedikian AY	2006	Int Ophthalmol Clin2006，46，1：	1
13	Phase Ⅲ study of docosahexaenoic acid paclitaxel versus dacarbazine in patients with metastatic malignant melanoma显示文摘	Bedikian AY DeConti RC Conry R	2011	Ann Oncol2011，22，4：	1
14	Phase 2 open-label study of weekly docosahexaenoic acid paclitaxel in patients with metastatic uveal melanoma显示文摘	Homsi J Bedikian AY Papadopoulos NE	2010	Melanoma Res2010，20，6：	1
15	Metastatic uveal melanoma therapy:current options显示文摘	Bedikian AY	2006	Int Ophthalmol Clin2006，46，：	1
16	Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma显示文摘	Bedikian AY Johnson MM Wameke CL	2008	Cancer Invest2008，26，6：	1
17	Sarcoma of the stomach: clinicopathologic study of 43 cases显示文摘	Bedikian AY Khankhanian N Valdivieso M	1980	J Surg Oncol1980，13，2：	1
18	Bcl-2 antisense (oblimersen sodium ) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group 显示文摘	Bedikian AY Millward M Pehamberger H	2006	J Clin Oncol2006，24，29：	1
19	Comparison of two dosing schedules of palonosetron for the prevention of nausea and vomiting due to interleukin-2-based biochemotherapy 显示文摘	Noor R Bedikian AY Mahoney S	2012	Sup- port Care Cancer2012，20，10：	1
20	Metastatic uveal melanoma therapy:current options显示文摘	Bedikian A Y	2006	Int Ophthalmol Clin2006，46，1：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示